← Back to Search

Automatic Self Transcending Meditation for Quality of Life

N/A
Waitlist Available
Led By Monali Malvankar, PhD
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first office visit, week 0, 4, 6, 8, 12, and 24

Summary

Patients with glaucoma will be randomized to Automatic Self Transcending Meditation (ASTM) plus Treatment as Usual (TAU) or TAU alone to assess changes in Health-related quality of life (HRQoL). HRQoL is a vital construct focusing on impact of health on quality of life. HRQoL data is used in economic evaluations, a component of health economics that compares the cost and consequences of alternative courses of action. This helps policy-makers make complex financial decisions. Along with HRQoL we will measure changes in extent of depression as well as anxiety. Previously published data lacks information of HRQoL in patients with glaucoma. Through this study we shall attempt to correlate HRQoL in this population and assess if ASTM confers changes in HRQoL along with depressive and anxiety symptoms.

Eligible Conditions
  • Quality of Life
  • Depression
  • Anxiety
  • Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first office visit, week 0, 4, 6, 8, 12, and 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and first office visit, week 0, 4, 6, 8, 12, and 24 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Health-related quality of life (HRQoL)
Secondary study objectives
Anxiety
Depression
Visual Function Score

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Automatic Self Transcending MeditationActive Control1 Intervention
Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.Research suggests that ASTM may help reduce depression and anxiety.
Group II: Treatment as Usual (TAU)Placebo Group1 Intervention
The usual standard of care for patients with glaucoma includes starting them on first line of drugs. Participants will be initiated and maintained on appropriate dosages of such medications as part of standard of care. The usual standard of care also includes an ophthalmic examination measuring best-corrected Snellen VA and pinhole acuities and a follow-up visit once a year.

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
677 Previous Clinical Trials
421,485 Total Patients Enrolled
Monali Malvankar, PhDPrincipal InvestigatorWestern University, Canada
1 Previous Clinical Trials
256 Total Patients Enrolled
~17 spots leftby Nov 2025